Last week, the firm launched AtheroGxOne the second of two cardiovascular next-gen sequencing panels, and hopes to launch its first liquid biopsy test in 2017.
The partners will develop panels to stratify patients with obesity and diabetes into surgical and alternate intervention groups in an upcoming clinical trial.
The New Jersey-based molecular diagnostics firm said it is planning to use the capital to "expand operations aggressively" and accelerate product development efforts.
NEW YORK (GenomeWeb News) – GeneWiz and Beijing ACCB Biotech today said they are collaborating on next-generation sequencing-based tests for the clinical market.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
